On August 23, 2023 CiMaas reported that it has filed a new patent application on a new method for the feeder cell preparation in support of its NK cell therapy program (Press release, CiMaas, AUG 23, 2023, View Source [SID1234634643]). Treatment with Natural Killer (NK) cells is the CiMaas strategy to potentially cure patients with cancer. CiMaas uses a feeder cell based NK cell expansion protocol to generate high NK cell numbers under GMP.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In general, a feeder cell line is exposed to high doses of ionizing radiation. By irradiating feeder cells, the cell division of the feeders is suppressed stopping their proliferation and thus preventing the overgrowth of the desired NK cells. CiMaas has invented and filed a patent describing a new method to halt the feeder cell division without irradiation and can perform this easily in house, without compromising the biological function of the feeder cells. This means we can prepare one step – frozen feeder cell batches, at lower costs, to expand NK cells in only 12 days. This product can be obtained for research as well as in clinical grade batches, please contact us at info @ cimaas.com. The patent inducing research has been supported by LIOF.